Evidence map›Paper›PMID 27817163›Full record

ArticleJournal of autism and developmental disorders2017

Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder.

Jeanne M Madden, Matthew D Lakoma, Frances L Lynch, Donna Rusinak, Ashli A Owen-Smith, Karen J Coleman, Virginia P Quinn, Vincent M Yau, Yinge X Qian, Lisa A Croen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of autism and developmental disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 5 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Jeanne M MaddenDepartment of Pharmacy and Health Systems Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Avenue R218X TF, Boston, MA, 02115, USA. j.madden@northeastern.edu.
Matthew D LakomaDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Frances L LynchThe Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
Donna RusinakDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Ashli A Owen-SmithSchool of Public Health, Georgia State University, Atlanta, GA, USA.
Karen J ColemanDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Virginia P QuinnDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Vincent M YauDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Yinge X QianDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Lisa A CroenDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Kaiser Permanente · USGeorgia State University · USHarvard Pilgrim Health Care · USHarvard University · USKaiser Permanente Center for Health Research · USMcKesson (United States) · USNortheastern University · US

Funding

SSRI's and SuicidalityU19MH092201 · NIMH · KAISER FOUNDATION RESEARCH INSTITUTE · PI SIMON, GREGORY E. · 2010 to 2018
$19.5M
NIMH NIH HHS U19 MH092201
6 · The paper itself

Abstract

This study examined psychotropic medication use among 7901 children aged 1-17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5 %) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2 %), antipsychotics (20.5 %), and antidepressants (17.8 %). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7 % overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation.

Indexed as

AdolescentAdrenergic Uptake InhibitorsAntidepressive AgentsAntipsychotic AgentsAtomoxetine HydrochlorideAutism Spectrum DisorderCase-Control StudiesCentral Nervous System StimulantsChildChild, PreschoolFemaleHumansInfantInsurance, HealthMalePsychotropic DrugsAdrenergic Uptake InhibitorsAntidepressive AgentsAntipsychotic AgentsAtomoxetine HydrochlorideCentral Nervous System StimulantsPsychotropic DrugsAntipsychoticsAutism spectrum disorderComorbiditiesEpidemiological studiesMedications

Identifiers

PMID27817163
PMCPMC5328123
OpenAlexW2548247840

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.